Divulging the Clinical Development of LTI-03 in IPF

Time: 9:40 am
day: Day Two

Details:

  • Assessing the “dual threat” of LTI-03: inhibition of the profibrotic process and lung regenerative effects
  • Uncovering how biomarkers could be used to reveal these properties

Speakers: